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Abstract
Clinical reports, primarily with Parkinson’s patients, note an association between the prescribed
use of pramipexole (and other direct-acting dopamine agonist medications) and impulse control
disorders, particularly pathological gambling. Two experiments examined the effects of acute
pramipexole on rats’ impulsive choices where impulsivity was defined as selecting a smaller-
sooner over a larger-later food reward. In Experiment 1, pramipexole (0.1 to 0.3 mg/kg)
significantly increased impulsive choices in a condition in which few impulsive choices were
made during a stable baseline. In a control condition, in which impulsive choices predominated
during baseline, pramipexole did not significantly change the same rats’ choices. Experiment 2
explored a wider range of doses (0.01 to 0.3 mg/kg) using a choice procedure in which delays to
the larger-later reinforcer delivery increased across trial blocks within each session. At the doses
used in Experiment 1, pramipexole shifted choice toward indifference regardless of the operative
delay. At lower doses of pramipexole (0.01 & 0.03 mg/kg), a trend toward more impulsive choice
was observed at the 0.03 mg/kg dose. The difference in outcomes across experiments may be due
to the more complex discriminations required in Experiment 2; i.e., multiple discriminations
between changing delays within each session.
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The Diagnostic and Statistical Manual of Mental Disorders (4th ed., text revision DSM-IV-
TR; American Psychiatric Association, 2000) classifies pathological gambling (PG) as one
of several impulse control disorders. Several recent clinical reports suggest that individuals
diagnosed with Parkinson’s disease (PD) who are treated with dopamine (DA) agonist
medications may demonstrate increased impulsivity and gambling activities which in some
cases reaches pathological levels (for a review see Potenza et al., 2007). Other cases of DA
agonist-related problem behavior have involved compulsive shopping and hypersexuality
(Dodd et al., 2005; Driver-Dunckley et al., 2007; Giovannoni et al., 2000; Klos et al., 2005;
McKeon et al., 2007; Munhoz et al., 2009; Voon et al., 2006a; Weintraub et al., 2006); two
activities also classified by the DSM-IV-TR as impulse control disorders. A causal role of
these DA agonist medications in the development of impulsive behaviors is suggested by the
absence (or socially acceptable frequency) of impulse control disorders prior to drug therapy
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and the subsequent resolution of the problematic behavior once drug use is discontinued
(e.g., Mamikonyan et al., 2008).
Dodd et al. (2005) reviewed the literature on problem gambling in PD patients and reported
that 84% of the reported cases of PG occurred while patients were taking one of three DA
agonists: pramipexole (59%), pergolide, or ropinirole (25% of the cases combined).
Similarly, in a prospective prevalence study, Voon et al. (2006b) reported that 7.2% of their
PD patients prescribed one of these three DA agonists (either as monotherapy or combined
with levodopa) currently or in the past met DSM-IV diagnostic criteria for PG after they
began taking the DA agonist medication. None of the patients taking levodopa alone were
diagnosed with PG (see Garcia et al., 2007; Grosset et al., 2007; Imamura et al., 2008; and
Weintraub et al., 2006 for similar findings). When Voon et al. (2006a) included
hypersexuality and compulsive shopping as instances of impulse control disorders, 13.7% of
PD patients taking one of these three DA agonists engaged in abnormal impulsive behavior
after taking the agonist alone or combined with levodopa. Szarfman et al. (2006) examined
cumulative reports of gambling incidents in the May 2005 US Food and Drug
Administration’s Adverse Event Reporting System. They found that among the 4,400 drugs
in the system, these same three DA agonists accounted for 76.1% of the reports of gambling
incidents; with pramipexole accounting for 58% of all gambling-related reports in the FDA
records.
Our experiments focused on pramipexole, which is a DA D2/D3 receptor agonist with high
selective affinity for the D3-receptor subtype (Bennett & Piercey, 1999). DA D3 receptors
are expressed predominantly in the mesocorticolimbic dopamine pathway (Grace, 2002;
Sokoloff et al., 1990, 2006). Limbic structures in this region are more active during
impulsive decision making (e.g., McClure et al., 2004, 2007) and play an important role in
drug cues reinstating drug self-administration (e.g., See, 2005). Conversely, expression of
DA D3 receptors in the prefrontal cortex is low (Levesque et al., 1992). The latter brain
region is thought to play an important role in executive function (Miller & Cohen, 2001),
forgoing impulsive choice (McClure et al., 2004, 2007), and tends to be hypoactive in drug-
dependent populations (e.g., Hester & Garavan, 2004).
To date, only two experiments have examined the effects of pramipexole on gambling-like
activities or impulsivity. Riba et al. (2008) reported that 0.5 mg pramipexole had no effect
on healthy male volunteers’ decisions to wager small or large amounts of money (5 or 25
Euro cents), but it did increase the probability of making a second large wager when the
preceding one was followed by an unexpected big win (50 Euro cents). The other
experiment examined the effects of pramipexole on impulsive choice using a delay-
discounting procedure in which humans chose between hypothetical monetary rewards
delivered immediately or following a delay (Hamidovic et al., 2008). Acute pramipexole
(0.25 & 0.5 mg) did not significantly increase impulsive choices. However, there was a
nonsignificant trend toward more impulsive choices at the higher dose, and the sample size
(n = 8) was smaller than is typical of human studies using similar delay-discounting
procedures (e.g., Richards et al., 1999).
In sum, the clinical literature suggests a linkage between DA D2/D3 agonists and impulse
control disorders, such as pathological gambling, but these reports lack appropriate control
conditions or systematic replication. The experimental research with pramipexole and
impulsive/risky choices is small and has yet to reveal systematic effects. Therefore, the
present research experimentally investigated the effect of acute pramipexole on impulsive
decision making in rats. Impulsivity was defined as selecting a small amount of food
delivered immediately while forgoing a larger amount of food available after a brief delay.
This definition of impulsivity captures many of the features of impulse control disorders
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outlined by the DSM-IV-TR (e.g., a choice which demonstrates an inability to resist
immediate temptation and results in a long-term loss; in this case, a loss of within-session
“income”). The social validity of this definition of impulsivity is suggested by studies
demonstrating substantial differences in this form of impulsivity between drug-addicted and
control participants (e.g., Madden et al., 1997; Vuchinich & Simpson, 1998) and between
pathological gamblers and controls (e.g., Alessi & Petry, 2003; Dixon et al., 2003, 2006;
Petry, 2001). Finally, studying the effects of pramipexole on impulsive choice in rats allows
for an examination of the effects of the drug against a known behavioral baseline.
Experiment 1
Method
Subjects—Nine male Wistar rats (Harlan Sprague-Dawley, Indianapolis, IN) served as
subjects. Seven rats had prior experience choosing between small-immediate and large-
delayed food reinforcers and were approximately 6 months old at the start of this
experiment. The remaining two rats (G1B1 & G1B2) were experimentally naïve and were 3
months old at the start of the experiment. Rats were weighed daily and maintained at
approximately 85% of free-feeding growth curve weights through supplemental, post-
session feeding provided 120 min after each session. Between sessions, rats were housed
individually in plastic cages within a temperature-controlled colony room providing a 12:12
hr light/dark cycle (lights on at 6:00 am). Water was available continuously in the home
cage. All procedures were approved by the Kansas University Animal Care and Use
Committee and conformed to the guidelines established by the NIH Guide for the Use of
Laboratory Animals.
Apparatus—Nine identical operant chambers (Med Associates, St. Albans, VT) were
used. Each chamber measured 24.1 cm wide, 30.5 cm long, and 21 cm high. One wall of the
chamber was an intelligence panel equipped with a nonretractable center lever (11 cm above
the floor) and two retractable side levers (horizontally aligned 11 cm apart and 6.5 cm above
the floor). Above each lever was a white, 28-volt cue light (2.5 cm in diameter and 6 cm
above each lever). A feeder (Coulbourn Instruments, Allentown, PA) equipped with a pellet
detection unit (Pinkston et al., 2008) delivered 45-mg grain-based food pellets (Bio-serv,
Frenchtown, NJ; no. F0165) into a receptacle in the center of the intelligence panel (3 cm
wide and 4 cm long) equipped with a 28-volt light (1 cm above the floor and 10 cm below
the center lever). Chambers were enclosed within a light- and sound-attenuation cubicle
(Med Associates, St. Albans, VT) equipped with a ventilation fan and a white noise speaker.
A Med Associates® interface system controlled the sessions and collected data.
Procedures—For the two naïve rats, lever pressing was autoshaped (Brown & Jenkins,
1968). Prior to beginning the experiment proper, all rats completed several sessions in which
responses alternated between pressing the left and right side levers to earn food reinforcers.
This ensured that the rats had a recent history of equivalent responding and reinforcement on
both of the side levers.
For the remainder of the experiment, sessions were composed of 42 trials, organized into
seven blocks of six trials. Each block consisted of two forced-choice trials (randomized with
one on the left lever and the other on the right) followed by four free-choice trials. The light
above the center lever signaled the start of every trial. On forced-choice trials, a response on
the center lever extinguished the cue light and caused one side lever to be inserted into the
chamber with the light above that lever simultaneously lit. A single response on the side
lever retracted the lever and began the pellet delivery sequence. During this sequence, either
the light above the lever was extinguished and one food pellet was delivered immediately
(0.01-s delay; the smaller-sooner reinforcer [SS]), or the light flashed in 0.25-s intervals
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during a delay after which three pellets were delivered (the larger-later reinforcer [LL]) and
the cue light was extinguished. A flash of light in the food receptacle accompanied the
delivery of each pellet.
Pellet deliveries were followed by an inter-trial interval (ITI) during which no stimuli were
presented. The duration of the ITI was adjusted to ensure that the start of each trial was
separated by exactly 100 s regardless of response latency and delay associated with the lever
selected. Within each trial, a 30-s limited hold was in effect: If either center- or side-lever
response latency exceeded 30 s following the illumination of the relevant cue light, the trial
was terminated, the ITI was initiated, and the trial was scored as an omission.
Each rat completed two conditions, with five rats completing these in one sequence and the
other four rats in the other sequence. In one condition, a baseline of self-control (i.e., 0–20%
choice of the SS reinforcer) was established to determine if pramipexole would increase
impulsive choices. The other condition established a baseline of impulsive choices (80–
100% SS choices) which served as a control: From a baseline of stable impulsive choices
would pramipexole increase choice of the LL reinforcer? If it did, then any effect of
pramipexole on choice in the self-control baseline would be attributable to a drug-related
non-specific disruption of choice. The assignment of the SS and LL reinforcers to the left
and right levers was counterbalanced across rats (see Table 1). It should be noted that prior
to this condition, the experienced rats made choices between SS and LL rewards with delay
to the LL adjusted in an attempt to produce a baseline of indifference. Stable indifference
proved to be difficult to achieve and could not be reliably recovered following drug sessions.
Therefore the two baseline procedures described below were pursued.
Self-control baseline—Sessions were conducted as described above with the delay to the
LL reinforcer set at 6 s. After each session, if the percentage of free-choices emitted on the
SS lever was greater than 20% for three consecutive sessions, then the delay to the LL
reinforcer was decreased by 2 s. After choice of the SS reinforcer initially fell in the 0–20%
range, all subsequent delay adjustments were in 1 s increments. In an attempt to maintain
some choice of the SS reinforcer within each session, the delay to the LL reinforcer was
increased by 1 s if the rat chose the LL alternative on all free-choice trials for three
consecutive sessions. This between-session adjusting-delay procedure was continued until
(a) SS choices were at or below 20% for ten consecutive sessions, (b) at least one of the
stable sessions contained nonexclusive choice, and (c) no omissions occurred in the stable
sessions. Once a stable baseline had been achieved, pre-session injections were initiated (see
below) and no further adjustments to the delay could be made. The delays at which each rat
stabilized in each condition are shown in Table 1. Rats that first completed the self-control
baseline condition also completed the impulsive baseline condition after all pre-session
pramipexole injections had been administered.
Impulsive baseline—With two exceptions this condition was identical to the self-control
baseline condition. First, the delay to the LL reinforcer was increased by 1 s if the
percentage of free-choices emitted on the SS lever was less than 80% for two consecutive
days. Second, this delay was decreased by 1 s if a subject exclusively chose the SS
alternative in all free-choice trials for three consecutive days. The stability criteria outlined
above were used here except that the range of SS choices was required to be at or above
80% (i.e., predominantly impulsive choices). Rats assigned to complete this condition first
also completed the self-control baseline condition after all pre-session pramipexole
injections had been administered.
Pharmacological procedures—Pramipexole was provided by Drs. Shaomeng Wang
and Jianyong Chen (University of Michigan, Ann Arbor, MI). Pramipexole was dissolved in
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physiological saline. Three doses of pramipexole (0.1, 0.18, 0.3 mg/kg) or saline vehicle
were administered subcutaneously 10 min prior to the session at a volume of 1.0 ml/kg. This
range of doses has been shown to be behaviorally active (e.g., Collins et al., 2005), while
higher doses have been found to greatly decrease locomotor activity during the post-
injection period in which our sessions were conducted (Lagos et al., 1998).
Drug tests were separated by no-injection days in which sessions were completed as usual.
No-injection days continued until choice was in the baseline range for at least four
consecutive days (median: 4.5; IQR: 4–5 days). The saline vehicle was given first and tests
with pramipexole followed in either an increasing or decreasing sequence (see Table 1).
Once each dose was tested, the series was repeated twice (in the same order) in both baseline
conditions.
Data analysis—Separate two-way (dose × series) repeated-measures ANOVAs were
conducted to determine if pramipexole significantly affected omissions, response latencies,
and impulsive choice (SPSS 16.0, SPSS Inc., Chicago, IL). Where data were not normally
distributed and remained significantly non-normal following standard transformations,
Greenhouse-Geisser corrected degrees of freedom were used. Bonferroni t-tests were used
for post hoc comparisons.
Results
In the self-control baseline condition (≥ 80% choice of the LL reinforcer), an average of
79.2 (SE = 16.5) sessions were required to reach an average stable adjusted-delay of 6.4 s
(SE = 1.2 see Table 1). In the impulsive baseline condition, an average of 89.3 (SE = 13.4)
sessions were required to achieve a stable adjusted-delay of 24.0 s (SE = 1.9). In one
condition, two rats’ (B1P1 & G1B2) stable baseline choices could not be recovered during
no-injection days between the second and third series of doses. These rats did not complete
the third dose series and missing data from this series were interpolated by SPSS using the
between-subjects average. These interpolations did not affect the outcome of any analysis.
The top panel of Figure 1 shows the average percent of trials on which the rat failed to
respond within 30 s (an omission) in the vehicle (V) and pramipexole sessions. When
compared with vehicle, pramipexole dose-dependently increased the number of trials scored
as omissions in both the impulsive (F(3, 48) = 30.8, p < .001, ηp2= 0.79; linear contrast: p < .
001) and self-control (F(1.5, 17.4) = 15.3, p = .001, ηp2= 0.66; linear contrast: p = .001)
baselines. The difference in omission frequencies across the two baseline conditions
approached, but did not achieve conventional levels of significance (main effect of baseline,
p = .06). No interactions were significant. A separate two-way ANOVA revealed no
significant main effect of series (i.e., the first, second, or third pass through the sequence of
saline and active injections, p = .17) and the dose × series interaction was not significant (p
= .45).
As shown in the bottom panel of Figure 1, pramipexole similarly affected center-lever
response latencies on trials in which a response was made. The main effect of dose was
significant in both the impulsive (F(3, 48) = 17.3, p < .001, ηp2= 0.68; linear contrast: p = .
001) and self-control baselines (F(3, 48) = 16.9, p < .001, ηp2= 0.68; linear contrast: p < .
001); however, no significant difference in latencies was observed across baselines (p = .17).
A separate two-way ANOVA revealed no significant main effect of series (p = .93) and the
dose × series interaction was not significant (p = .71).
In five sessions in which injections were administered (2.2% of all injection sessions), four
rats failed to complete any free- or forced-choice trials (one rat did this twice at the highest
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dose). This occurred twice in the self-control baseline and three times in the impulsive
baseline and was restricted to the two highest doses (0.18 and 0.3 mg/kg). In these cases, the
missing data were interpolated from between-subject averages; these interpolations did not
affect the outcome of any analysis.
The top panel of Figure 2 shows the average percentage of impulsive choices made in the
self-control baseline condition. Separate data paths illustrate the effects of pramipexole in
the three dosing series. In this condition, impulsive choices were infrequent on vehicle (V)
days. By contrast, pramipexole increased impulsive choices above saline levels (F(3,48) =
21.3, p < .001; ηp2= 0.73; linear contrast: p < .001). The main effect of dosing series was not
significant (p < .48). However the dose × series interaction approached significance (p = .
06), reflecting the higher prevalence of impulsive choices on the final dosing series at the
highest dose.
In the impulsive baseline condition (bottom panel of Figure 2), impulsive choices
predominated in vehicle sessions. No significant main effect of pramipexole was detected (p
= .34); however, there was a significant effect of dosing series (F(2,48) = 9.5, p < .01; ηp2=
0.54) reflecting a reduction in impulsive choice at the 0.3 mg/kg dose in the first, relative to
the second and third, series of pramipexole doses. Where this reduction was observed (three
sessions), it occurred in sessions in which more than 60% of the trials were omitted (i.e., the
trial was terminated because the rat failed to respond within 30 s).
To reduce the probability that conclusions about the effects of pramipexole on impulsive
choice would be influenced by sessions in which few choice responses occurred, a second
series of analyses were conducted in which data were excluded if the rat did not complete at
least 50% of the free-choice trials. This exclusion criterion resulted in the exclusion of 7.4%
of the data in the self-control baseline condition and 10.8% in the impulsive baseline
condition. To allow statistical analyses with these missing data, a single average was
calculated at each dose for each rat across dosing series. These data are shown in Figure 3.
As before, a significant effect of pramipexole was observed in the self-control baseline
condition (F(3,24) = 16.1, p < .001; ηp2= 0.67), but not in the impulsive baseline (p = .12).
Post-hoc comparisons of self-control baseline choices revealed significant differences
between saline and all pramipexole doses (p < .03 in all cases); however, no significant
differences were detected between doses. In the impulsive baseline, post-hoc comparisons
revealed no differences between doses or between any single dose and saline.
Discussion
At doses ranging from 0.1 to 0.3 mg/kg, pramipexole significantly increased impulsive
choices in male Wistar rats. From a stable self-control baseline, the average minimum
increase in impulsive choice was 31% (range: 4 to 72%) and the average maximum increase
was 50% (range: 13 to 92%). These increases would appear not to be due to a disruption in
choice produced by active doses of pramipexole. If this were the case, choice should have
been disrupted similarly from the baseline of stable impulsive choice. This, however, was
not the case. From a stable impulsive baseline, the average pramipexole-related change in
impulsive choice ranged from −4 to 7%.
Further evidence against this choice-disruption hypothesis comes from two putative
measures of response disruption – center-lever response latencies (i.e., trial-initiation
responses) and omissions (i.e., trials in which latencies exceeded 30 s). For both measures,
pramipexole produced similar dose-related disruptions during both the impulsive and self-
control baseline conditions. If longer latencies and/or more omissions had been observed in
the self-control baseline, one might reasonably argue that choice too was more disrupted by
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pramipexole in this condition. However, no difference in latencies was observed across
conditions, and there was a trend toward more omissions in the impulsive baseline condition
(p = .06); the opposite of what one would expect if increased impulsive choices in the self-
control condition were due to drug-related disruptions in responding.
While these findings provide preliminary evidence that pramipexole increased impulsive
choice in male Wistar rats, it is important to note that, with a few exceptions, the drug did
not produce strong preferences for the SS over the LL reward. Three rats chose the SS
reward >60% of the time at the 0.18 and 0.3 mg/kg doses, but the rest did not. Thus,
pramipexole increased impulsive choice, but it did so only to the point of indifference
between a SS and a LL reinforcer. Given this tendency toward indifference, the possibility
must be considered that choice in the self-control baseline may have been more easily
disrupted by any perturbation than was choice in the impulsive baseline condition. Indirect
evidence supporting this hypothesis is provided by Experiment 4 of Nevin (1974). In this
study, pigeons’ pecked a single key on a multiple schedule of reinforcement. In one
component of the multiple schedule, pecks were reinforced immediately (0.4-s signaled
delay), while in the other component reinforcers were delayed (9.6-s signaled delay). When
free food was delivered during a blackout period (a standard disruptor in studies of this type)
the percentage decrease below baseline response rate was larger in the component in which
the pigeon had previously obtained delayed reinforcers. If this outcome, obtained in a single-
response context, can be translated to the choices made in the two baselines of the present
experiment, then one might expect strong preference for a delayed reinforcer (self-control
baseline condition) to be more susceptible to disruption than a comparable (but opposite)
preference for an immediate reinforcer (impulsive baseline condition). If so, then the shift
toward more impulsive choices observed in the self-control baseline of Figure 3 may be
more related to non-specific choice-disrupting effects of pramipexole than to any
impulsivity-increasing effects of this drug. Arguing against this hypothesis are findings
suggesting that drugs such as cocaine do not serve as behavioral disruptors in tests of
behavioral momentum (Cohen, 1986; Harper, 1999; Pinkston et al., 2009).
Nonetheless, to begin to address this alternative account of the results of Experiment 1,
Experiment 2 employed a commonly used procedure for assessing drug effects on impulsive
choice. In this procedure, developed by Evenden and Ryan (1996), the delay to the larger
food reward is initially set at zero and is progressively increased across trial blocks within
each session. According to the choice-disruption hypothesis just described, choice should be
least disruptable in the first trial block because all reinforcers are immediate. In subsequent
trial blocks, as more delayed rewards are selected, choice should be more disruptable and
preference should shift toward indifference. However, if pramipexole increases impulsive
choice, then (barring a floor effect) it should decrease choice of the LL reinforcer in all trial
blocks except the first.
Experiment 2
Method
Subjects and Apparatus—Twelve experimentally naïve male Wistar rats (Harlan
Sprague-Dawley, Indianapolis, IN), approximately 3 months old at the start of the
experiment, served as subjects. Rats were housed as in Experiment 1 and were provided
supplemental feeding to maintain their weight at 85% of adult free-feeding weight. All
procedures were approved by the Kansas University Animal Care and Use Committee.
Procedures—Initial training was accomplished as with the experimentally naïve rats in
Experiment 1. Once lever pressing was reliably occurring on all three levers, the experiment
began. The procedures used in the experimental sessions were based on those outlined by
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Evenden and Ryan (1996). Sessions were composed of 40 trials presented in blocks of 10
trials. Each block was composed of four forced- and then six free-choice trials. Two forced-
choice trials were completed on each lever in random order. Forced- and free-choice trials
operated as in Experiment 1. The lever to which the LL reward was assigned was
counterbalanced across subjects (see Table 2).
The delay to the larger food reward was increased within-session between trial blocks. In
block 1, the delay to the larger reward was 0 s, so the rat simply chose between more (3
pellets) and less (1 pellet) food. Within the second, third, and fourth trial blocks the delay to
the larger reward was set at 10, 20, and then 30 s (in that order). In addition to the forced-
choice trials, two procedures were used throughout the experiment to enhance the salience
of the between-block changes in delays. First, trial blocks were separated by a 180-s
blackout. Second, on a randomly determined one out of seven days, no delay was imposed
between choice and delivery of the larger reward in any trial block. This no-delay procedure,
originally used by Evenden and Ryan (1996), may increase the probability that subjects
attend to the delays arranged in each trial block, rather than to the passage of time or
signaled transitions between trial blocks.
Stability of choice within each trial block was assessed after a minimum of 20 baseline
sessions. Within a block, choice was considered stable when the mean percent LL choice
over the last 6 sessions differed from the previous 6-session mean by no more than 10%
with no monotonic trend. Baseline sessions continued until these stability criteria were met
in all four trial blocks and no omissions occurred in the last 12 sessions. Of the 12 rats that
began the experiment, 3 demonstrated either hyper- or hypo-sensitivity to the within-session
delay increases during no-injection sessions (floor and ceiling effects, respectively). These
rats were excluded from the study because their baseline preference for the LL reward could
only increase (hypersensitivity to delay) or only decrease (hyposensitivity).
Pharmacological procedures—Pramipexole (0.01, 0.03, 0.1, 0.18, 0.3 mg/kg) or saline
vehicle was administered subcutaneously 10 min prior to the session at a volume of 1.0 ml/
kg. The lower doses were added after it was observed that doses of 0.1 and above disrupted
preference for the large over the small reinforcer during the first trial block (0-s delay to
both rewards). Two rats had already completed the first series of 0.1–0.3 mg/kg doses before
this decision was made. Therefore, for these rats, the smaller doses were included only in the
second and third dose series. The lower doses have been found to be behaviorally active
(e.g., Collins et al., 2005; Lagos et al., 1998).
Within each dosing series, saline vehicle was given first and tests with pramipexole
followed in a descending order of doses. The descending order was selected because we
have occasionally observed in previous work with dopamine agonists that the effects of
smaller doses change after the administration of larger doses, and so beginning the sequence
with the larger dose minimizes variability. Once each dose was tested, the series of doses
was repeated twice (in the same order). Drug tests were separated by four no-injection
sessions. Pramipexole was not administered during the occasional sessions in which the
delay remained at zero throughout.
Data analysis—A preliminary two-way (dose × series) repeated-measures ANOVA was
used to evaluate if the effects of pramipexole varied as a function of repeated series of doses.
To include delay within this analysis, area under the percent LL choice curve was calculated
for each subject at each dose. Because no main effect of series or dose × series interaction
was detected, the choice data were collapsed across series in the remaining analyses. A two-
way (dose × delay) repeated-measures ANOVA was conducted to determine if pramipexole
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significantly affected percent impulsive choice. Bonferroni-corrected t-tests were used for
post hoc comparisons.
Results & Discussion
Figure 4 shows that as delays to the LL reward were increased within the session, percent
choice of this reward significantly declined during saline sessions (F(3,32) = 31.5, p < .001).
There was no significant difference between saline and no-injection sessions (F(1,24) = 0.19,
p > .05) and the latter data are omitted from the graphs. Also not shown are choices made
during sessions in which the delay remained at 0 s through all trial blocks. Across rats, the
larger reward was selected 98.9% of the time in the first trial block, and declined in the three
subsequent trial blocks to 94.4, 92.1, and 93.3%. A one-way ANOVA revealed that this
decline was significant (F(3,24) = 6.25, p < .01) and Bonferroni-corrected post hoc
comparisons revealed that choice of the larger reward was significantly higher in trial block
1 than in block 4 (p ≤ .02) but not blocks 2 or 3 (p’s > .08).
The upper panel of Figure 4 shows Experiment 2 choices made at the doses used in
Experiment 1. At these doses the percent choice of the larger food reward was significantly
decreased in the first trial block in which both rewards were immediately available
(Bonferroni corrected p < .05 at all three doses). This outcome is not consistent with the
alternative account of the results of Experiment 1. That is, if choices maintained by
immediate rewards are less susceptible to disruptors (such as a non-specific effect of a drug)
then choice in the first trial block of Experiment 2 should have been as difficult to disrupt, as
was choice in the impulsive baseline of Experiment 1.
Similar shifts toward indifference were observed at the 30-s delay (significant at the 0.1 and
0.18 mg/kg doses; p < .05). At the Experiment 1 doses, pramipexole flattened the choice
function (toward indifference) at all delays but 20 s; the delay at which indifference was
observed in saline sessions. This flattening was dose dependent, as linear functions fit to
choices made at each dose revealed significantly more shallow slopes when 0.1 mg/kg was
compared with saline and 0.3 mg/kg was compared to 0.1 mg/kg (p < .05 in both cases).
Because the doses of pramipexole used in Experiment 1 significantly shifted choice toward
indifference in these first and final trial blocks, the remainder of the choice curve could not
be interpreted as a drug effect on impulsive choice. Therefore, the data were not further
analyzed.
The lower panel of Figure 4 shows the effects of the two lower doses of pramipexole on
choice, exclusively used in Experiment 2. These doses did not shift choice toward
indifference in either the initial or final trial block (0 and 30 s, respectively); thus, any
significant reductions in choosing the LL reward at the 10- and 20-s delays could be
interpreted as a drug related increase in impulsivity. Across all delays, there was no
significant main effect of dose (p = .13) or delay × dose interaction (p = .19). Post-hoc tests
conducted at the 10- and 20-s delays failed to reveal a significant increase in impulsive
choice at either of the low doses of pramipexole. However, the differences at 0.03 mg/kg
approached significance at the 10- and 20-s delays (one-tailed p’s = .04 and .03,
respectively; which fell short of the critical value of the Bonferroni adjusted p = .01).
Although this experiment started with 12 rats, 3 were excluded from dosing because their
baseline choices made it impossible to see either an increase or a decrease in impulsivity;
hyper- or hypo-sensitivity to delay, respectively. The smaller than anticipated sample size of
9 rats may have been insufficient to detect the effects of the 0.01 and 0.03 mg/kg doses.
Thus, future research should employ additional subjects and may benefit from exploring
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doses between 0.03 and 0.1 mg/kg. These doses may produce a significant increase in
impulsive choice while not disrupting choice in the first and final trial blocks.
General Discussion
Two experiments examined the effects of acute pre-session pramipexole injections on rats’
impulsive choice. In Experiment 1, acute pramipexole at doses between 0.1 and 0.3 mg/kg
significantly increased impulsive choice. The same doses did not significantly disrupt choice
(toward indifference) in a control baseline in which the rats preferred the SS reinforcer. The
second experiment employed a procedure in which delays to the LL reinforcer were
increased within session. In Experiment 2, acute pramipexole in the 0.1–0.3 mg/kg range
produced a non-specific disruption of choice (toward indifference). These choice-disrupting
effects were not observed at lower acute doses (0.01 and 0.03 mg/kg), but the highest of
these two doses produced only a trend toward more impulsive choice.
Experiment 1 included a control condition in which the effects of pramipexole were
examined from a baseline of predominantly impulsive choices (i.e., preference for the SS
reinforcer). Because acute pramipexole at doses ranging from 0.1 to 0.3 mg/kg did not
disrupt choice in this impulsive baseline, there is reason to believe that the significant
increase in impulsive choice observed in the self-control baseline was due to an impulsivity-
inducing effect of pramipexole, rather than a non-specific disruption of discriminations
underlying choice. The caveat to this interpretation is that choice in the self-control baseline
may have been more easily disrupted than in the other baseline because the consequences
maintaining choice in the self-control baseline were delayed reinforcers.
Experiment 2 was designed to address this alternative explanation by examining the effects
of the same doses of pramipexole when immediate reinforcers followed all choices at the
beginning of the session (presumably producing the least choice disruption) and when
reinforcers became progressively more delayed through the remainder of the session.
Contrary to expectation, acute pramipexole (0.1–0.3 mg/kg) significantly disrupted choice in
the first block of choice trials when all reinforcers were delivered immediately.
Why pramipexole disrupted choice in the first block of trials in Experiment 2 but not in the
impulsive baseline of Experiment 1 deserves comment. One hypothesis is that stimulus
control was more strongly established in Experiment 1 than in Experiment 2. Strong
stimulus control in Experiment 1 might be expected because the same outcomes followed
presses on the left and right levers throughout each session and throughout each baseline (a
period of approximately 150 days of consistent outcomes within each baseline). By contrast,
in Experiment 2 the delay to the larger reinforcer increased from 0 to 30 s within-session
across trial blocks. This may have decreased the likelihood that the lever and cue light
associated with the larger reward would acquire as strong a delay-cuing function as was
established in Experiment 1. The finding that behavior under weak stimulus control is more
sensitive to the rate-altering effects of drugs than behavior under strong stimulus control
(Laties, 1975; Laties & Weiss, 1966; Moerschbaecher, Boren, Schrot, & Fontes, 1979) may
help to explain the choice disruptions observed in Experiment 2 at doses employed in
Experiment 1. If these speculations are correct, then Experiment 2 may not have adequately
tested the alternative account of the results of Experiment 1. Clearly more research is
necessary.
Three future research directions are suggested by the present findings and their relation to
clinical reports of increased impulse control disorders among PD patients treated with
pramipexole. First, because PD patients take daily doses of pramipexole, often for months or
more before the development of impulse control disorders, future research should examine
the effects of chronic pramipexole on impulsive choice. Second, there may be merit in
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exploring the effects of pramipexole in Parkinson’s rats, as this is the group of humans who
have most often been reported to develop PG when given this drug or other dopamine
agonists (Ondo & Lai, 2008); although it should be noted that a number of clinical reports
have documented a relation between pramipexole and impulse control disorders in
individuals treated for restless leg syndrome (Potenza, 2007). Third, the role of DA, and
how it might interact with the serotonergic system to affect impulsive choice is not well
understood (Winstanley, 2009). While the present findings tentatively suggest a role of DA
D2 and D3 receptors in impulsive choice, this hypothesis was not directly tested by
comparing the effects of pramipexole with those of other drugs such as DA agonists that
affect different DA receptors or DA receptor-specific antagonists.
To conclude, the present findings tentatively support the hypothesis that pramipexole
increases impulsivity when defined as preference for a smaller-sooner over a larger-later
reinforcer. The link between pramipexole and impulse control disorders (such as human
pathological gambling) must be interpreted with caution because the term impulsivity has
several meanings (see Evenden, 1999), only one of which was measured in the present
experiments. Although human pathological gamblers favor smaller-sooner over larger-later
rewards (see Petry & Madden, 2009 for a review), the role that this form of impulsivity may
play on the decision to gamble remains theoretical (e.g., Madden et al., 2007; Rachlin,
1990).
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Average (SEM) percent of trials omitted per session (top panel) and mean center lever
response latency (bottom panel) as a function of saline and pramipexole doses in Experiment
1.
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Average (SEM) percent choice of the impulsive (SS) alternative in impulsive and self-
control baseline conditions of Experiment 1.
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Average (SEM) percent choice of the impulsive (SS) alternative in impulsive and self-
control baseline conditions of Experiment 1. Data were excluded from analysis if the rats
completed fewer than 50% of free-choice trials in a session.
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Average (SEM) percent choice of the LL reward as a function of LL delay across trial
blocks in Experiment 2. The top panel displays choices made at the same doses used in
Experiment 1. The bottom panel shows choices made at two smaller doses.
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